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Objectives. This study sought to compare, in post-myocardial
infarction patients, baroreflex sensitivity (BRS) measured by the
phenylephrine method (Phe-BRS) with that estimated by the
Robbe (Robbe-BRS) and Pagani (alpha-low frequency [LF] and
alpha-high frequency [HF]) spectral techniques.
Background. BRS assessed by Phe-BRS has been shown to be of
prognostic value in patients with a previous myocardial infarc-
tion, but the need for drug injection limits the use of this
technique. Several noninvasive methods based on spectral analy-
sis of systolic arterial pressure and heart period have been
proposed, but their agreement with Phe-BRS has never been
investigated in post-myocardial infarction patients.
Methods. The linear association and the agreement between
each spectral measurement and Phe-BRS were assessed by corre-
lation analysis and by computing the relative bias and the limits
of agreement in 51 post-myocardial infarction patients.
Results. The correlation with Phe-BRS was r 5 0.63 for
Robbe-BRS, r 5 0.62 for alpha-LF and r 5 0.59 for alpha-HF. The
relative bias was significant for alpha-LF (2.6 ms/mm Hg, p <
0.001) and alpha-HF (2.5 ms/mm Hg, p 5 0.01) and not significant
(20.6 ms/mm Hg, p 5 0.3) for Robbe-BRS. The normalized limits
of agreement ranged from 298% to 95% for Robbe-BRS, from
267% to 126% for alpha-LF and from 2108% to 143% for
alpha-HF. When patients were classified according to left ventric-
ular ejection fraction (LVEF, cutoff value 40%), the relative bias
was higher in patients with a depressed LVEF, although statistical
significance was high only for Robbe-BRS and was borderline for
alpha-LF. The limits of agreement were similar in both groups of
patients (p > 0.3).
Conclusions. Despite a substantial linear association, the
agreement between spectral measurements and Phe-BRS in post-
myocardial infarction patients is weak because the difference can
be as large as the BRS value being estimated. Phe-BRS is the
measurement most associated with hemodynamic impairment.
Because several factors within each method contribute to the
overall difference, neither method can be defined as being better
than the other in estimating baroreflex gain, nor can one be used
as an alternative to the other. Ad hoc studies are needed to assess
which method provides the most useful physiologic or pathophys-
iologic information or the most accurate prediction of prognosis.
(J Am Coll Cardiol 1998;31:344–51)
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Baroreceptor reflex sensitivity (BRS) in humans has been
mainly assessed by pharmacologic methods, administering
agents that cause changes in blood pressure but do not directly
affect heart rate (1–3). These techniques measure the reflex
heart rate response to a pharmacologic activation or deactiva-
tion of the arterial baroreceptors. It was recently demonstrated
(4–6) that BRS as assessed by the phenylephrine method is of
prognostic value in patients after myocardial infarction and
adds information to that obtained from traditional measures
such as left ventricular ejection fraction (LVEF) and ventric-
ular arrhythmias (6). However, although the availability of
noninvasive pressure monitors has greatly simplified the appli-
cation of this technique (7), its widespread clinical use is
somewhat limited by the need for drug injection.
In recent years there have been several proposals (8–12) to
quantify BRS by using spectral techniques to analyze the
relation between spontaneous beat to beat oscillations of
systolic arterial pressure (SAP) and heart period (HP), on the
basis that the baroreflexes not only control abrupt changes in
arterial pressure, but are continuously activated by small
variations of SAP around the set point for that particular
patient or condition. These methods are very appealing as they
do not require the use of drugs, allow continuous monitoring
of the baroreflex gain and are simple and fast.
Despite substantial differences in the physiologic models on
which the pharmacologic and spectral methods are based,
several investigators (8,10,11,13) have proposed that the spec-
tral methods are reliable alternatives to the phenylephrine test,
on the basis of correlation analysis. However, their highly
promising results have been obtained only in small groups of
normal subjects and hypertensive patients; no data have been
reported for post-myocardial infarction patients.
The aim of this study was to analyze, in a sample of
postmyocardial patients, the agreement between the baroreflex
gain as assessed by two well established spectral techniques—
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those of Robbe et al. (8) and Pagani et al. (10)—and the value
obtained by the vasoactive drug phenylephrine. Preliminary
results have been presented (14). We also examined whether
the agreement between the two techniques was dependent on
the degree of impairment of left ventricular function. As each
of these methods has important limitations and none can be
considered the standard against which to compare the others,
we used appropriate techniques to assess the agreement be-
tween observed measurements.
Methods
Subjects and protocol. We studied 60 patients who had
been consecutively admitted to the Montescano Rehabilitation
Center after myocardial infarction. All patients had sinus
rhythm without evidence of peripheral neuropathy. The rate of
ectopic beats was #5% in each recording analyzed. All subjects
gave informed consent to the study, which was approved by the
local ethics committee. Nine patients were excluded from
analysis because one or more spectral indexes were not
computable because of a lack of coherence between SAP and
HP. This led to a final group of 51 patients with an average
time from myocardial infarction of 42 days (range 20 to 146).
Patients were classified into two groups according to the
median value of LVEF: In 25 patients, LVEF was depressed
(#40%) and in 26 it was preserved (.40%).
The experimental sessions for the spectral measurement of
the baroreflex gain and for the phenylephrine test were carried
out in the morning. After instrumentation (electrocardio-
graphic [ECG] monitor and the Finapres device), patients
were asked to lie supine. After a 15-min period for patient and
signal stabilization, the Finapres self-adjustment was discon-
nected and an 8-min recording of ECG and blood pressure
signals was performed.
After Finapres recalibration, the self-adjustment was
switched off once more and the phenylephrine test was per-
formed according to the Oxford technique (1) as previously
described (4). Briefly, phenylephrine (2 mg/kg body weight)
was given as an intravenous bolus to raise SAP by 15 to
40 mm Hg. When the pressure did not increase sufficiently,
additional injections were made with increments of 25 mg of
phenylephrine. At least three bolus injections were made at
10-min intervals at the dose that caused the desired increase in
SAP.
Signal acquisition. All analog signals were digitized with a
sampling rate of 250 Hz and stored in a personal computer for
subsequent analysis. The HP and SAP time series were com-
puted. A resolution of 1 ms was obtained for the HP time
series by using a linear interpolation algorithm on the filtered
first derivative of the ECG signal.
Spectral techniques. The 8-min HP and SAP time series
were then plotted together, and the longest portion of signals
free from artifacts or large transients having a minimal length
of 4.5 min was selected. This choice was a compromise between
the length used in the technique of Robbe et al. (4.5 min) (8)
and that used in the method of Pagani et al. (512 beats) (10).
Correction of ventricular premature complexes is manda-
tory when using spectral techniques to avoid spurious spectral
details while preserving the continuity of cardiovascular
rhythms (15). In our software this was performed by means of
a semiautomated procedure that substituted each couple of
aberrant beats with their average. According to the technique
of Robbe et al., bivariate spectral analysis between SAP and
HP time series was first performed (we used the Blackman-
Tukey approach with a Parzen window having a bandwidth of
0.015 Hz). The transfer function modulus and the coherence
function were also computed. The mean value of the transfer
function modulus in the frequency band 0.07 to 0.14 Hz,
considering only those points where the coherence was $0.5,
was taken as the measure of the baroreflex gain. We will refer
to this index as the Robbe-BRS.
To implement the method of Pagani et al., univariate and
bivariate spectral analysis was performed by using the autore-
gressive approach and related spectral decomposition tech-
niques (16). The baroreflex gain was quantified by performing
the following steps: 1) estimation of the spectrum of HP and
SAP and computation of spectral components in the low
frequency (LF) band (from 0.04 to 0.15 Hz) and in the high
frequency (HF) band (from 0.15 to 0.45 Hz); 2) estimation of
the coherence function; and 3) computation of the square root
of the ratio between the HP and the SAP spectral components
in both bands, provided that the coherence between these
components was .0.5. These two indexes are usually called
alpha-LF and alpha-HF, respectively. An example of the
computation of the spectral indexes of Robbe and Pagani et al.
is shown in Figure 1.
Analysis of the phenylephrine test data. Ectopic beats were
first removed from raw recordings of HP and SAP. Each
systolic pressure peak was associated with the subsequent RR
interval. The time series of HP and SAP changes with respect
to the corresponding median values during the preinjection
phase were then plotted together, and the analysis window was
defined as the interval between the beginning and the end of
Abbreviations and Acronyms
alpha-HF 5 baroreflex sensitivity measured by the high frequency
spectral method of Pagani et al. in the high
frequency band
alpha-LF 5 baroreflex sensitivity measured by the low frequency
spectral method of Pagani et al. in the low frequency
band
BRS 5 baroreflex sensitivity
HF 5 high frequency (0.15 to 0.45 Hz)
HP 5 heart period
LF 5 low frequency (0.04 to 0.15 Hz)
LVEF 5 left ventricular ejection fraction
Phe-BRS 5 baroreflex sensitivity measured by the phenylephrine
method
Robbe-BRS 5 baroreflex sensitivity measured by the spectral
method of Robbe et al. (8)
SAP 5 systolic arterial pressure
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the first increase in SAP $15 mm Hg. The slope of the
regression line relating HP changes to SAP changes in the
analysis window was automatically computed. Only regression
lines with a statistically significant slope (p , 0.05) were
accepted for analysis. A final slope was obtained by calculating
the mean value of at least three measurements. This index will
be referred to as Phe-BRS.
Data analysis. The linear association between spectral and
phenylephrine measurements was assessed by correlation anal-
ysis. The agreement of the two measurements was assessed by
analyzing the differences between them (spectral measure-
ment 2 phenylephrine measurement). A statistical model of
observed measurements was assumed (17) in which both the
phenylephrine and the spectral measurements are supposed to
be corrupted by two independent components of error: a
systematic component (commonly called “bias”) and a random
component (see Appendix). Hence, when the difference be-
tween the two measurements is considered, it is also consti-
tuted by a systematic term (called “relative bias”) and by a
random term that accounts for the random error of both
methods.
Following a well established and efficient approach (18), we
plotted the individual differences (for instance, the differences
between the Robbe-BRS and Phe-BRS measurements) as a
function of the average of the two measurements. The average
of the two measurements is the best estimate we can have of
the “true” value of the baroreflex gain of each subject. We also
computed the mean and the 95% confidence intervals of the
differences (the so-called limits of agreement [18]). The mean
difference estimates the relative bias or constant offset between
the two methods. The limits of agreement, in contrast, give a
realistic picture of the range of values within which 95% of
individual differences between the spectral and standard mea-
surements lie. The limits of agreement were also computed on
the normalized difference, obtained by dividing the difference
between two measurements by their mean value and multiply-
ing by 100. Hypothesis testing for the bias (null hypothesis:
bias 5 0) was performed by the one-sample t test; testing for
differences between groups was performed by the t test for
independent samples. Comparisons of the width of limits of
agreement were performed by the F test.
The agreement between the spectral and phenylephrine
measurements was also assessed by computing quartiles of the
variables and measuring the proportion of patients ranked
within the same quartiles by the two methods.
A p value # 0.05 was considered statistically significant.
When multiple comparisons were performed, the Bonferroni
correction was applied; for a family of three comparisons, this
implies a significance level of 0.014.
Results
The clinical characteristics of the patients are given in
Table 1.
Measurements by individual methods. Descriptive statis-
tics of the four BRS measurements for all patients and for
patients with depressed and preserved LVEF are reported in
Table 2. Although all BRS measures were lower in patients
with impaired than with preserved LVEF, only phenylephrine
measurements changed significantly, with a mean value in the
latter group being about twice that in the former. Alpha-LF
and alpha-HF data showed a higher value of mean BRS with
respect to Phe-BRS both in the overall group and in the two
subgroups. Moreover, these measurements were characterized
by a larger spread of the data among patients.
Figure 1. Example of the computation of the spectral indexes of
Robbe et al. and Pagani et al. Panels a and b show representative
examples of SAP and HP time series. The corresponding autoregres-
sive spectra are shown in panels c and d, respectively; the coherence
function between SAP and HP computed by autoregressive (solid line)
and by the Blackman-Tukey technique (dashed line) in panel e; and
the transfer function in panel f. The portion of the transfer function in
the frequency region 0.07 to 0.14 Hz, where the coherence is $0.5, is
plotted in bold. The mean value of this line is the Robbe-BRS index.
The darkened areas PLFSAP, PHFSAP, PLFHP and PHFHP in the two
spectra represent the spectral components involved in the computation
of the alpha-LF and alpha-HF, and the dashed-dotted lines in panels
c, d and e indicate the LF and HF central frequencies. The alpha-LF
is computed by dividing PLFHP (corresponding to the LF component of
HP) by the PLFSAP (corresponding to the LF component of SAP) and
taking the square root. The same holds for alpha-HF, considering the
areas PHFHP and PHFSAP.
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Agreement between measurements. Overall study group.
The scatterplots of each spectral estimate of BRS versus
phenylephrine measurements are shown in Figure 2. The
identity lines are also plotted. There is a substantial linear
association for all comparisons, as assessed by the correlation
coefficient (r ' 0.6). However, several points in all three plots
lie far from the line of identity, and all the spectral indexes
tend to overestimate low Phe-BRS values. Figure 3a displays
the Bland-Altman plot of the difference against the mean for
the comparison between the Robbe-BRS and the Phe-BRS
measurements. Differences as great as 210 ms/mm Hg can be
observed over a baroreflex gain ranging from ;1 to 25 ms/mm
Hg. This high dispersion of values is made evident by the limits
of agreement, which span from 29.0 to 7.7 ms/mm Hg. Hence,
95% of observed differences between the two methods are
expected to lie within this range, in other words, the Robbe-
BRS measure may underestimate the Phe-BRS by as much as
9 ms/mm Hg or overestimate it by as much as 7.7 ms/mm Hg.
The slight bias between the two measurements, which is
estimated by the mean difference, is not significant. Detailed
results are given in Table 3.
It is clear from Figure 3a that, owing to the lack of
homogeneity of the distribution of the differences over the
observed range of baroreflex gain, the computed limits of
agreement tend to be overestimated for low gain values and
underestimated for high values.
When the normalized difference (Fig. 4a) is considered, the
distribution becomes much more uniform. The corresponding
limits of agreement range from 298% to 95%. Hence, one can
expect the difference between the two measurements to be
almost as large as the baroreflex gain being estimated. Similar
considerations can be drawn from Figures 3b and 4b and
Table 1. Baseline Clinical Characteristics of the 51 Study Subjects
Age (yr) 52 6 9
Male 96%
Baseline heart period (ms) 880 6 140
Baseline SAP (mm Hg) 121 6 21
First MI 82%
Site of MI
Anterior 53%
Inferior 35%
Other 12%
Non-Q wave MI 14%
Thrombolytic therapy 41%
LVEF (%) 41 6 12
Time from MI (days) 42 6 26
Therapy*
Antiplatelet 78%
Beta-blocker 6%
ACE inhibitor 39%
Nitrate 35%
Diuretic drug 39%
Ca channel antagonists 18%
Digoxin 31%
*Therapy at the time of baroreflex sensitivity determination. Data are
presented as mean value 6 SD or number (%) of patients. ACE 5 angiotensin-
converting enzyme; Ca 5 calcium; MI 5 myocardial infarction; LVEF 5 left
ventricular ejection fraction; SAP 5 systolic arterial pressure.
Table 2. Phenylephrine and Spectral Measurements of Baroreflex
Gain in All Patients and Patients With LVEF #40% or .40%
All
Patients
(n 5 51)
LVEF
#40%
(n 5 25)
LVEF
.40%
(n 5 26)
p
Value*
Phe-BRS 9.1 6 5.3 6.5 6 3.2 11.6 6 5.8 , 0.001
Robbe-BRS 8.5 6 4.4 7.9 6 4.1 9.1 6 4.7 0.32
Alpha-LF 11.8 6 6.0 10.7 6 5.5 12.8 6 6.4 0.20
Alpha-HF 11.6 6 8.2 9.8 6 6.4 13.4 6 9.4 0.12
*Left ventricular ejection fraction (LVEF) #40% versus .40%. Data
presented are mean value 6 SD (ms/mm Hg). Alpha-HF and Alpha-LF 5
baroreflex sensitivity (BRS) measured by spectral method of Pagani et al. (10) in
the high and low frequency bands, respectively; Phe-BRS 5 BRS measured by
phenylephrine method; Robbe-BRS 5 BRS measured by spectral method of
Robbe et al. (8).
Figure 2. Scatterplots of the relation between spectral indexes of
baroreflex gain and phenylephrine test measurements (Phe-BRS). a,
Robbe index versus Phe-BRS; b, alpha-LF index versus Phe-BRS, c,
alpha-HF index versus Phe-BRS. The identity (dashed) line is also
plotted.
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Figures 3c and 4c, for the comparison, respectively, of
alpha-LF and alpha-HF with Phe-BRS. For these measure-
ments, however, a highly significant positive bias and larger
limits of agreement can be observed. When subjects were
ranked by quartiles, ,50% were equally classified by the two
methods (45% for Robbe-BRS, 45% for alpha-LF, 35% for
alpha-HF, all with respect to Phe-BRS).
Depressed and preserved LVEF. The results for patients
with reduced and preserved LVEF are given in Table 3.
Correlation coefficients between spectral measurements and
Phe-BRS were higher in the patients with LVEF .40% than in
those with LVEF #40%. However, none of these differences
was statistically significant (p . 0.1 for all comparisons).
In patients with impaired LVEF all spectral methods gave
higher estimates of BRS than did phenylephrine, but this
positive relative bias reached statistical significance only for
alpha-LF and alpha-HF. In patients with preserved LVEF, the
positive relative bias between alpha-LF and alpha-HF versus
Phe-BRS was lower than in patients with depressed LVEF.
However, this difference was not significant for alpha-HF (p 5
0.40) and was borderline for alpha-LF (p 5 0.033). Conversely,
it was negative and highly significant for Robbe-BRS (p ,
0.001). Concerning the width of the limits of agreement, the
two groups showed substantially similar results (p . 0.30 for all
three comparisons), indicating an equivalent magnitude of the
random component of the difference.
Figure 3. Bland-Altman plots of the difference between spectral
measurements of baroreflex gain and the same measurement obtained
by the phenylephrine method (Phe-BRS) against their mean value. a,
Differences between the index of Robbe et al. and Phe-BRS. b,
Differences between the alpha-LF index and Phe-BRS. c, Differences
between the alpha-HF index and Phe-BRS. Dashed lines indicate the
limits of agreement. Dashed-dotted lines indicate the mean difference
(bias).
Figure 4. Bland-Altman plots of the normalized difference between
spectral and phenylephrine measurements of baroreflex gain (Phe-
BRS) against their mean value. a, Normalized differences between the
index of Robbe et al. and Phe-BRS. b, Normalized differences between
the alpha-LF index and Phe-BRS. c, Normalized differences between
the alpha-HF index and Phe-BRS. Dashed lines indicate the limits of
agreement. Dashed-dotted lines indicate the mean difference (bias).
Table 3. Global Results of Comparison Between Spectral Measurements of Baroreflex Gain and Phenylephrine Measurement
All Patients (n 5 51) LVEF #40% (n 5 25) LVEF .40% (n 5 26)
Robbe-BRS Alpha-LF Alpha-HF Robbe-BRS Alpha-LF Alpha-HF Robbe-BRS Alpha-LF Alpha-HF
Correlation
coefficient
0.63 0.62 0.59 0.58 0.55 0.31 0.70 0.66 0.66
Relative bias
(ms/mm Hg)
20.6
(p 5 0.31)†
2.6
(p , 0.001)‡
2.5
(p 5 0.01)§
1.3*
(p 5 0.06)†
4.1
(p , 0.001)‡
3.3
(p 5 0.014)§
22.5
(p 5 0.006)†
1.2
(p 5 0.24)‡
1.7
(p 5 0.22)§
Limits of agreement
(ms/mm Hg)
29.0–7.7 27.1–12.4 210.5–15.5 25.3–8.0 24.9–13.1 28.8–15.4 210.7–5.7 28.6–11.0 212.1–15.6
Normalized limits of
agreement (%)
298–95 267–126 2108–143 272–114 247–144 2101–169 2103–56 274–95 2109–112
*p , 0.001, LVEF # 40% versus LVEF . 40%. †Robbe-BRS versus Phe-BRS. ‡Alpha-LF versus Phe-BRS. §Alpha-HF versus Phe-BRS. Abbreviations as in Table 2.
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Discussion
The present investigation shows that in a group of patients
with previous myocardial infarction, despite a substantial lin-
ear association, the agreement between BRS obtained by
spectral techniques and by the phenylephrine test is rather
weak, as the difference between the two measurements can be
as large as the baroreflex gain being estimated.
The alpha-LF and alpha-HF indexes showed a positive
systematic offset with respect to Phe-BRS in patients with
depressed or preserved LVEF. The Robbe index, in contrast,
showed a positive offset in patients with depressed LVEF and
a negative offset in the other group. The limits of agreement
were similar in the two groups.
Several theoretic and methodologic factors may account for
the observed lack of agreement between spectral and phenyl-
ephrine measurements: different physiologic conditions under
which the gain of the baroreflex is measured, differences in the
models of cardiovascular regulation on which each method is
based and measurement error due to signal conditioning,
processing algorithms and analysis criteria.
Disagreement due to physiologic difference. There are four
major differences in the physiologic conditions under which the
phenylephrine and spectral measurements of baroreflex gain
are taken. 1) The pressure change induced during the phenyl-
ephrine test basically overrides both the pressure to pressure
reflexes (through changes in peripheral resistance, arterial and
venous compliance, heart contractility and other factors) and
the heart rate-pressure feedforward mechanism, thus approx-
imating an open loop condition. Spectral measurements, in
contrast, are based on spontaneous fluctuations of SAP and
heart rate and are taken with all reflexes and control mecha-
nisms fully active, that is, in a closed loop condition. Hence,
significant differences in the relation between SAP and HP in
the two conditions are likely. 2) The phenylephrine method
requires a ramp increase of SAP of $15 mm Hg, giving rise to
a certain degree of baroreceptor “stretching,” whereas spon-
taneous oscillations of systolic pressure usually span a few mm
Hg around its set point. 3) The ramp increase in pressure
associated with phenyleprine injection is a different stimulus
for the baroreceptors than the “oscillatory” stimulus that is
implicitly assumed by spectral techniques. These methods, in
fact, are all based on the notion of “spectral component” or
“cardiovascular rhythm,” in both the LF and HF bands, which
is based on the experimental observation of quasi-periodic
oscillations in these bands (12). 4) The peripheral vasoconstric-
tion induced by phenylephrine may cause the activation of
other receptors like cardiopulmonary mechanoreceptors (as a
result of increased afterload) and exert a direct effect on the
vessel walls of carotid and aortic arteries, which might in turn
modify their firing rate. The former effect may be more
pronounced in patients with left ventricular dysfunction, thus
acting as a potential confounder on HP changes induced by the
drug.
Differences in modeling assumptions. Each of the four
techniques considered in this study (Phe-BRS, Robbe-BRS,
alpha-LF and alpha-HF) implicitly assumes a model of short-
term pressure regulation (19). Depending on the appropriate-
ness of these models to the underlying physiologic mecha-
nisms, the estimated BRS will be more or less accurate, adding
further variability to the differences among the considered
methods. The phenylephrine method, for instance, assumes
that each HP value is related to the previous SAP peak and
that this relation is linear (1). However, it has been suggested
(20) that a more accurate model should represent each RR
interval as a function of at least a few preceding beats, to take
into account the slower sympathetic influences as well. The
method of Robbe et al. basically assumes an open loop model
relating SAP to HP even though signals, as noted, are actually
analyzed in a closed loop condition. Finally, the spectral
method for baroreflex gain estimation proposed by Pagani et
al. assumes a closed loop model, where changes in SAP induce
changes in HP and these, in turn, affect SAP (10), but a few
major simplifications are made to allow for mathematic solu-
tion. In fact external disturbances are supposed to affect only
SAP, which is equivalent to assuming that fluctuations in HP
are almost entirely driven by blood pressure fluctuations alone
through the baroreceptors (i.e., all other central or reflex
influences on the sinoatrial node are negligible) (19). Baselli et
al. (19) showed elegantly from a mathematic point of view that
the application of this model simplification is the cause of a
positive bias (up to 41%) in alpha-LF and alpha-HF indexes
compared with Robbe-BRS. Our study results confirm these
theoretic expectations as the relative bias of alpha-LF and
alpha-HF is consistently greater than that of Robbe-BRS (see
Table 3).
Measurement error. The lack of agreement between Phe-
BRS and spectral indexes of baroreflex gain is partly depen-
dent on measurement error of both quantities. Although the
design of this study does not allow for the estimation of the
magnitude of measurement error, its possible sources can be
discussed. One source could be related to the fact that spectral
indexes of baroreflex gain are obtained from recordings differ-
ent from those used to estimate Phe-BRS. We (21) have
previously shown that the precision of Finapres measurements
is lower in the postinjection phase than in stationary condition.
Well recognized sources of variability in the phenylephrine
method are mainly due to the rate of injection, the steepness of
arterial pressure increase and the subjective choice of the
window for the analysis (1). Accordingly, averaging the results
of at least three consecutive responses has been proposed in
order to increase measurement precision.
Two main sources of measurement error are relevant in the
estimation of spectral indexes: the statistical instability of
spectral estimates, due to the finite record length of the time
series analyzed (22), and the signal to noise ratio of the signals
within the frequency bands in which the indexes are computed.
Concerning the first issue, although increasing the record
length increases statistical stability, in practical analysis there
are two main limitations: 1) the stationarity requirement for
spectral estimation (which is difficult to satisfy in long records),
and 2) the need for periodic readjustment of the Finapres
349JACC Vol. 31, No. 2 MAESTRI ET AL.
February 1998:344–51 BRS BY SPECTRAL AND PHENYLEPHRINE TECHNIQUES
device. On the basis of results of a previous investigation (23),
we argue that the record length selected for this study, which is
a reasonable compromise between the Robbe-BRS Pagani-
BRS methods, is an adequate choice. Concerning the second
issue, reduced power of the LF and HF bands, has been
associated (24) with patients with left ventricular dysfunction,
thus implying a lower level of the signals of interest (i.e.,
spontaneous LF and HF oscillations) with respect to contam-
inating noise. This in turn would give rise to lower coherence
values and a related higher positive bias of alpha-LF and
alpha-HF indexes (see previous paragraph).
The accuracy of BRS estimates also depends on the com-
putation criteria adopted in the application of each method. In
estimating Phe-BRS, for instance, the algorithm used is unique
(i.e., simple linear regression) and the acceptance of each
computed slope depends solely on its statistical significance. In
spectral methods, in contrast, results are dependent on the
spectral algorithm used and on related analysis criteria (such as
type and width of the spectral window, order of the autore-
gressive model, threshold for coherence).
Although several drugs are known to affect the autonomic
balance, for patients under treatment the medication schedule
did not differ between the times of phenylephrine and spectral
BRS assessment.
Previous studies. Spectral estimation of baroreflex gain has
been validated in small samples of normal subjects or hyper-
tensive patients (8,10,13). These studies have shown that the
different methods are significantly related.
We obtained a correlation coefficient between alpha-LF
and Phe-BRS of 0.62 and between alpha-HF and Phe-BRS of
0.59; both values are quite similar to those Pagani et al. (10)
obtained for the same indexes in 11 hypertensive subjects. Our
correlation coefficient of 0.63 between Robbe-BRS and Phe-
BRS is slightly higher than that (r 5 0.48) obtained by Watkins
et al. (13) using a similar methodology in 42 normotensive and
borderline hypertensive subjects. Conversely, Robbe et al.
observed an excellent correlation coefficient of 0.94 in eight
healthy volunteers. The reasons for these discrepancies are not
clear, but we can speculate that they might depend on the
lower coherence we found in our patients (median coherence
0.6, range 0.5 to 0.8) compared with that in the normal subjects
studied by Robbe et al. (median coherence 0.8, range 0.4 to
0.95); the different sample size (51 subjects vs. 8); and the
different range of the baroreflex sensitivity taken into consid-
eration (1 to 27 ms/mm Hg in our study, 7 to 27 ms/mm Hg in
the study of Robbe et al.).
However, use of the correlation coefficient to assess the
agreement between two measurement methods has been crit-
icized (18). For example, this value depends on the range of
observed measurements and is unable to distinguish between
linear relations lying along the line of identity and any other
kind of linear relation (18). To overcome these limitations we
adopted the simple and powerful technique of computing the
bias and the limits of agreement. Manually deriving these
parameters from the scatterplot shown in the report of
Watkins et al. (13), we found a larger bias with an opposite sign
('28.1 ms/mm Hg) to that found in our study, and a similar
magnitude of limits of agreement ('2153% to 31%).
Role of ventricular dysfunction. The average value of
Phe-BRS was significantly different between patients with
reduced and preserved LVEF, whereas this difference was no
longer significant for spectral indexes, thus suggesting a greater
dependence of Phe-BRS on the degree of ventricular dysfunction.
The correlation coefficients between phenylephrine and
spectral indexes tended to be lower in patients with depressed
LVEF, indicating a higher proportion of uncorrelated infor-
mation between the two measurements in this subgroup of
patients. This would suggest that impaired LVEF might em-
phasize the different physiologic conditions under which BRS
is assessed (see earlier). Indeed, in the presence of an in-
creased sympathetic drive as observed in patients with de-
pressed LVEF, small changes in HP induced by small changes
in SAP (as quantified by spectral techniques) are likely to be
preserved, whereas a greater increase of HP after a
phenylephrine-induced increase in SAP (.15 mm Hg) may be
limited. Moreover, in the presence of left ventricular dysfunc-
tion a significant increase in afterload by causing a further
hemodynamic impairment, may activate other mechanisms
(reduction in rate of rise of left ventricular pressure [dP/dt] of
the pulse waveform, cardio-cardiac reflexes) which interfere
with the reflex bradycardia induced by phenylephrine, ulti-
mately leading to an underestimation of BRS. This hypothesis
is consistent with our data as shown by the higher relative bias
for alpha-LF and alpha-HF and by the change from negative to
positive in the bias of Robbe-BRS. However, the possibility
that the model simplifications applied for alpha-LF and
alpha-HF spectral measurements overestimate the baroreflex
gain to a greater extent in patients with a more impaired LVEF
has also to be taken into account.
Nevertheless, despite a different bias, the random compo-
nent of measurement error, as shown by the limits of agree-
ment, is similar in patients with preserved and depressed
LVEF, confirming that spectral indexes and Phe-BRS cannot
be used as alternatives in either patient groups.
The relation between BRS and the function of the left
ventricle (in patients with a previous myocardial infarction) is
of particular interest. Because the derangement in neural
endings at the infarct site associated with changes in left
ventricular geometry and myocardial contractility are the likely
causes of the impaired baroreflex gain after myocardial infarc-
tion, a logical expectation would be that the larger the infarct
size (and, accordingly, the greater the left ventricular dysfunc-
tion), the lower the baroreflex gain. Although a previous report
found no linear association between Phe-BRS and LVEF in
patients without clinical signs of heart failure after myocardial
infarction, in a larger series of postmyocardial infarction
patients (25) Phe-BRS was significantly lower among subjects
with more severe ventricular dysfunction. However, even in the
present larger series, the lack of a significant linear relation
between Phe-BRS and LVEF did not allow us to consider BRS
after phenylephrine injection as an index of the status of
ventricular function.
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Clinical implications and conclusions. As several factors
within each method contribute to the overall difference
(systematic and random) between Phe-BRS and spectral in-
dexes, neither method can be considered better than the other
in estimating baroreflex gain nor used alternatively to the other
without a great chance of marked errors. Further investiga-
tions are needed to assess which method provides the most
useful physiologic or pathophysiologic information or the most
accurate prediction in prognosis. Our data and data from other
studies suggest that the agreement between the pharmacologic
and spectral techniques and their applicability may depend on
the patient group considered. In postmyocardial infarction
patients we found a weak agreement between the indexes in
patients with depressed and more preserved LVEF. Lower
values of baroreflex gain were observed when using the
phenylephrine technique as compared to spectral measures in
patients with impaired LVEF.
Appendix
The Statistical Model
The basic statistical model assumed for the measurement of baroreflex
sensitivity has the form:
xik 5 pi 1 ak 1 eik, [1]
where xik is the measurement taken on subject i with the kth method
(k 5 1, 2, 3, where 1 represents phenylephrine, 2 the method of
Robbe et al. and 3 the method of Pagani et al.); ak is the bias of the
kth method; pi is the true value (also called “true score” or “steady
state value”) of the baroreflex sensitivity of the subject; and eik
represents a random contribution due to the measurement process
that is supposed to be independent of pi, have zero mean and fixed
variance.
To study the agreement between the kth spectral method (k 5 2, 3)
and the phenylephrine method, their difference is first computed:
dik 5 xik 2 xi1 5 ak 2 a1 1 eik 2 ei1 5 Dak 1 hik, [2]
where Dak represents the relative bias and can be easily estimated by
computing the mean d# k of the observed differences between the two
measurements. The standard deviation of the hik term can be esti-
mated by the sample standard deviation sk of the same differences.
Assuming dik to be normally distributed, the 95% limits of agree-
ment are defined as (18):
d#k 6 1.96zsk. [3]
References
1. Smyth HS, Sleight P, Pickering GW. Reflex regulation of arterial pressure
during sleep in man: a quantitative method of assessing baroreflex sensitivity.
Circ Res 1969;24:109–21.
2. Pickering TG, Gribbin B, Petersen ES, Cunningham DJC, Sleight P.
Comparison of the effect of exercise and posture on the baroreflex in man.
Cardiovasc Res 1971;5:582–6.
3. Pickering TG, Gribbin B, Sleight P. Comparison of the reflex heart response
to rising and falling arterial pressure in man. Cardiovasc Res 1972;6:277–83.
4. La Rovere MT, Specchia G, Mortara A, Schwartz PJ. Baroreflex sensitivity,
clinical correlates, and cardiovascular mortality among patients with a first
myocardial infarction: a prospective study. Circulation 1988;78:816–24.
5. Farrel TG, Paul V, Cripps TR, et al. Baroreflex sensitivity and electrophys-
iological correlates in patients after acute myocardial infarction. Circulation
1991;83:945–52.
6. La Rovere MT, Bigger JT Jr, Marcus FI, et al on behalf of the ATRAMI
Investigators. Prognostic value of depressed baroreflex sensitivity: the
ATRAMI study [abstract]. Circulation 1995;92 Suppl I:I-676.
7. La Rovere MT, Mortara A, Pinna GD, et al for the ATRAMI Investigators.
Quantification of baroreflex sensitivity by FINAPRES in patients after
myocardial infarction: the ATRAMI experience. J Am Coll Cardiol 1997;29
Suppl A:470A.
8. Robbe HWJ, Mulder LJM, Ruddel H, Langewitz WA, Veldman JBP,
Mulder G. Assessment of baroreceptor reflex sensitivity by means of spectral
analysis. Hypertension 1987;10:538–43.
9. Akselrod S, Gordon D, Madwed JB, Snidman NC, Shannon DC, Cohen RJ.
Hemodynamic regulation: investigation by spectral analysis. Am J Physiol
1985;249 (Heart Circ Physiol 18):867–75.
10. Pagani M, Somers V, Furlan R, et al. Changes in autonomic regulation
induced by physical training in mild hypertension. Hypertension 1988;12:
600–10.
11. Parati G, Omboni S, Frattola A, Di Rienzo M, Zanchetti A, Mancia G.
Dynamic evaluation of the baroreflex in ambulant subjects. In: Di Rienzo M,
Mancia G, Parati G, Pedotti A, Zanchetti A, editors. Blood Pressure and
Heart Rate Variability. Amsterdam, The Netherlands: IOS Press, 1992:123–
37.
12. Honzikova N, Fiser B. Spectral analysis of circulatory rhythms and baroreflex
sensitivity in man. In: Haken H, Koepchen HP, editors. Rhythms in
Physiological Systems. Berlin-Heidelberg: Springer-Verlag, 1991:97–102.
13. Watkins LL, Grossman P, Sherwood A. Noninvasive assessment of barore-
flex control in borderline hypertension: comparison with the phenylephrine
method. Hypertension 1996;28:238–43.
14. Maestri R, Pinna GD, La Rovere MT, Mortara A, Tavazzi L. Baroreflex gain
by spectral analysis in patients after myocardial infarction: comparison with
the phenylephrine method [abstract]. J Am Coll Cardiol 1997;29 Suppl
A:469A.
15. Saul JP, Arai Y, Berger RD, Lilly LS, Colucci WS, Cohen RJ. Assessment of
autonomic regulation in chronic congestive heart failure by heart rate
spectral analysis. Am J Cardiol 1988;61:1292–9.
16. Johnsen SJ, Andersen N. On power estimation in maximum entropy spectral
analysis. Geophysics 1978;43:681–90.
17. Dunn G. Design and analysis of reliability studies. Stat Meth Med Res
1992;1:123–57.
18. Bland MJ, Altman DG. Statistical methods for assessing agreement between
two methods of clinical measurement. The Lancet 1986;8:307–10.
19. Baselli G, Porta A, Ferrari G. Models for the analysis of cardiovascular
variability signals. In: Malik M, Camm AJ, editors. Heart Rate Variability.
Armonk (NY): Futura, 1995:135–45.
20. de Boer RW, Karemaker JM, Strakee J. Hemodynamic fluctuations and
baroreflex sensitivity in humans: a beat-to-beat model. Am J Physiol.
1987;253 (Heart Circ Physiol 18):680–9.
21. Pinna GD, La Rovere MT, Di Cesare A, Mortara A. Time course accuracy
of the non-invasive blood pressure measurements in the assessment of the
neural control of the cardiovascular system. In: Di Rienzo M, Mancia G,
Parati G, Pedotti A, Zanchetti A, editors. Blood Pressure and Heart Rate
Variability. Amsterdam, The Netherlands: IOS Press, 1992:109–17.
22. Pinna GD, Maestri R, Di Cesare A. Application of time series spectral
analysis theory: analysis of cardiovascular variability signals. Med Biol Eng
Comput 1996;34:142–8.
23. Pinna GD, Maestri R, Sanarico M. Effects of record length selection on the
accuracy of spectral estimates of heart rate variability: a simulation study.
IEEE Trans Biomed Eng. 1996;43:754–7.
24. Mortara A, La Rovere MT, Signorini MG, et al. Can power spectral analysis
of heart rate variability identify a high risk subgroup of congestive heart
failure patients with excessive sympathetic activation: a pilot study before
and after heart transplantation. Br Heart J 1994;71:422–30.
25. Mortara A, Specchia G, La Rovere MT, et al, on behalf of the ATRAMI
Investigators. Patency of infarct-related artery: effect of restoration of
anterograde flow on vagal reflexes. Circulation 1996;93:1114–22.
351JACC Vol. 31, No. 2 MAESTRI ET AL.
February 1998:344–51 BRS BY SPECTRAL AND PHENYLEPHRINE TECHNIQUES
